
TELA Bio, Inc. – NASDAQ:TELA
TELA Bio stock price today
TELA Bio stock price monthly change
TELA Bio stock price quarterly change
TELA Bio stock price yearly change
TELA Bio key metrics
Market Cap | 111.95M |
Enterprise value | 180.42M |
P/E | -4.12 |
EV/Sales | 3.00 |
EV/EBITDA | -3.00 |
Price/Sales | 3.03 |
Price/Book | 12.75 |
PEG ratio | 0.71 |
EPS | -1.67 |
Revenue | 63.14M |
EBITDA | -43.40M |
Income | -40.29M |
Revenue Q/Q | 39.41% |
Revenue Y/Y | 40.02% |
Profit margin | -113.06% |
Oper. margin | -98.39% |
Gross margin | 64.26% |
EBIT margin | -98.39% |
EBITDA margin | -68.73% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTELA Bio stock price history
TELA Bio stock forecast
TELA Bio financial statements
Jun 2023 | 14.49M | -10.79M | -74.44% |
---|---|---|---|
Sep 2023 | 15.05M | -10.95M | -72.79% |
Dec 2023 | 16.99M | -12.89M | -75.83% |
Mar 2024 | 16.60M | -5.66M | -34.1% |
Sep 2025 | 25.24M | -6.27M | -24.88% |
---|---|---|---|
Oct 2025 | 24.8M | -5.89M | -23.79% |
Dec 2025 | 27.65M | -5.57M | -20.16% |
Dec 2025 | 27.46M | -5.16M | -18.79% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 94386000 | 54.38M | 57.62% |
---|---|---|---|
Sep 2023 | 87317000 | 56.76M | 65.01% |
Dec 2023 | 78048000 | 59.16M | 75.81% |
Mar 2024 | 71837000 | 57.45M | 79.98% |
Jun 2023 | -11.26M | -157K | 46.40M |
---|---|---|---|
Sep 2023 | -6.96M | -134K | 71K |
Dec 2023 | -11.05M | -193K | 22K |
Mar 2024 | -14.38M | 4.69M | 56K |
TELA Bio alternative data
Aug 2023 | 173 |
---|---|
Sep 2023 | 173 |
Oct 2023 | 173 |
Nov 2023 | 173 |
Dec 2023 | 173 |
Jan 2024 | 173 |
Feb 2024 | 173 |
Mar 2024 | 227 |
Apr 2024 | 227 |
May 2024 | 227 |
Jun 2024 | 227 |
Jul 2024 | 227 |
TELA Bio other data
Period | Buy | Sel |
---|---|---|
Nov 2023 | 21000 | 0 |
Dec 2023 | 2600 | 0 |
Jun 2024 | 0 | 378000 |
Jul 2024 | 0 | 50300 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | ORBIMED ADVISORS LLC 10 percent owner | Common Stock | 36,600 | $4.54 | $166,164 | ||
Sale | ORBIMED ADVISORS LLC 10 percent owner | Common Stock | 13,700 | $4.68 | $64,116 | ||
Sale | ORBIMED ADVISORS LLC 10 percent owner | Common Stock | 378,000 | $4.74 | $1,791,720 | ||
Purchase | FIRESTONE GREGORY A. officer: Chief Business Officer | Common Stock | 2,600 | $5.65 | $14,687 | ||
Purchase | CUCA ROBERTO officer: COO and CFO | Common Stock | 10,000 | $4.49 | $44,940 | ||
Purchase | KOBLISH ANTONY director, officer.. | Common Stock | 11,000 | $4.54 | $49,973 | ||
Sale | ORBIMED ADVISORS LLC 10 percent owner | Common Stock | 27,700 | $9.41 | $260,657 | ||
Sale | ORBIMED ADVISORS LLC 10 percent owner | Common Stock | 28,300 | $9.43 | $266,869 | ||
Sale | ORBIMED ADVISORS LLC 10 percent owner | Common Stock | 136,000 | $9.3 | $1,264,800 | ||
Option | BURGESS VINCENT J director | Common Stock | 4,860 | $4.44 | $21,578 |
Patent |
---|
Application Filling date: 18 May 2022 Issue date: 1 Sep 2022 |
Grant Filling date: 28 Aug 2019 Issue date: 28 Jun 2022 |
Grant Utility: Corner-lock stitch patterns Filling date: 25 Feb 2019 Issue date: 31 May 2022 |
Application Filling date: 8 Mar 2019 Issue date: 24 Dec 2020 |
Application Filling date: 6 Jul 2020 Issue date: 22 Oct 2020 |
Application Filling date: 4 Jun 2020 Issue date: 24 Sep 2020 |
Application Filling date: 9 Mar 2020 Issue date: 10 Sep 2020 |
Application Filling date: 14 Feb 2020 Issue date: 13 Aug 2020 |
Grant Utility: Surgical attachment device Filling date: 19 Jul 2016 Issue date: 7 Jul 2020 |
Grant Filling date: 15 Nov 2017 Issue date: 18 Feb 2020 |
Quarter | Transcript |
---|---|
Q1 2024 11 May 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 21 Mar 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 12 Nov 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
Insider | Compensation |
---|---|
Mr. Antony Koblish (1966) Co-founder, Pres, Chief Executive Officer & Director | $806,250 |
Dr. E. Skott Greenhalgh Ph.D. (1968) Chief Technology Officer | $488,630 |
-
What's the price of TELA Bio stock today?
One share of TELA Bio stock can currently be purchased for approximately $1.76.
-
When is TELA Bio's next earnings date?
Unfortunately, TELA Bio's (TELA) next earnings date is currently unknown.
-
Does TELA Bio pay dividends?
No, TELA Bio does not pay dividends.
-
How much money does TELA Bio make?
TELA Bio has a market capitalization of 111.95M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 41.13% to 58.45M US dollars.
-
What is TELA Bio's stock symbol?
TELA Bio, Inc. is traded on the NASDAQ under the ticker symbol "TELA".
-
What is TELA Bio's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of TELA Bio?
Shares of TELA Bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are TELA Bio's key executives?
TELA Bio's management team includes the following people:
- Mr. Antony Koblish Co-founder, Pres, Chief Executive Officer & Director(age: 59, pay: $806,250)
- Dr. E. Skott Greenhalgh Ph.D. Chief Technology Officer(age: 57, pay: $488,630)
-
Is TELA Bio founder-led company?
Yes, TELA Bio is a company led by its founder Mr. Antony Koblish.
-
How many employees does TELA Bio have?
As Jul 2024, TELA Bio employs 227 workers.
-
When TELA Bio went public?
TELA Bio, Inc. is publicly traded company for more then 5 years since IPO on 8 Nov 2019.
-
What is TELA Bio's official website?
The official website for TELA Bio is telabio.com.
-
Where are TELA Bio's headquarters?
TELA Bio is headquartered at 1 Great Valley Parkway, Malvern, PA.
-
How can i contact TELA Bio?
TELA Bio's mailing address is 1 Great Valley Parkway, Malvern, PA and company can be reached via phone at +48 43202930.
TELA Bio company profile:

TELA Bio, Inc.
telabio.comNASDAQ
227
Medical - Devices
Healthcare
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Malvern, PA 19355
CIK: 0001561921
ISIN: US8723811084
CUSIP: 872381108